Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study is a double blind, randomized, investigator initiated study on glucose-lowering
effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2
Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy. The primary aim of
the study is to compared changes of HbA1c between 0.25mg robeblitazone add-on group and 0.5mg
robeglitazone add-on group.